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For many years clinicians have speculated that
abnormal sodium metabolism plays an important
role in the pathogenesis of hypertension. This con-
sideration probably has been most evident in ob-
stetrical practices directed toward preventing hy-
pertensive disorders of pregnancy. it was common-
ly assumed that normal gestation was associated
with sodium-retaining tendencies, which were
thought to be causally related to the development of
preeclampsia. Accordingly, pregnant women cus-
tomarily were treated as though threatened by ex-
cessive sodium retention; dietary salt restriction
and diuretics were prescribed routinely as pre-
cautionary measures.
In view of this concern, it is quite understandable
that the discovery of aldosterone and the recogni-
tion of its causal relationship to hypertension in
Conn's syndrome quickly led early investigators to
study the possible pathogenic role of this potent
mineralocorticoid in the hypertensive disorders of
pregnancy. Initial reports suggesting that aldoste-
rone levels were higher in preeclamptic than in non-
pregnant women generated considerable excite-
ment, which quickly was tempered by the observa-
tion that aldosterone secretion was increased to an
even greater extent in normal gravidas [1]. Since
then, results of numerous studies have provided
confirmation that aldosterone levels are markedly
elevated in normal gravidas compared with non-
pregnant women on similar salt intakes [2, 3]. More
recently, it has been shown that secretion of anoth-
er potent mineralocorticoid, desoxycorticosterone,
also is increased substantially during normal preg-
nancy [4, 5]. Nonetheless, normal gravidas do not
demonstrate clinical evidence of mineralocorticoid
excess, and the blood pressure falls below preg-
nancy values during the first two trimesters.
Received for publication January 18, 1980
0085-2538/80/0018-0162 $02.20
© 1980 by the International Society of Nephrology
162
Although the regulation of aldosterone secretion
in pregnancy has been studied extensively, the
physiologic significance of the markedly increased
secretion of aldosterone remains controversial.
There is considerable evidence that normal preg-
nancy results in a tendency towards a reduced f-
fective blood volume, despite the high levels not on-
ly of aldosterone and desoxycorticosterone, but al-
so of estrogens, which have sodium-retaining
effects in man. Thus, some propose that the en-
hanced secretion of aldosterone is a compensatory
response required to maintain normal volume
homeostasis [6]. Others argue that the augmented
extracellular and intravascular fluid volumes mea-
sured in normal pregnancy, as well as the accom-
panying rise in cardiac output and in the GFR, are
inconsistent with functional hypovolemia, and sug-
gest that these changes more likely reflect sodium
retention induced by aldosterone hypersecretion
[7].
Questions regarding the role of increased aldoste-
rone in pregnancy, whether it is associated with a
tendency to lose or to retain sodium, not only have
a bearing upon routine management of pregnant
women, but are also of fundamental importance to
our understanding of the pathophysiology of the
gestational hypertensive disorders. In attempting to
resolve these issues, it would seem appropriate to
review studies that might help to define the role of
increased mineralocorticoids in normal pregnancy.
Aldosterone in pregnancy
Aldosterone in pregnancy starts to rise above the
normal range almost as soon as pregnancy is estab-
lished and continues to increase steadily throughout
the course of gestation, as shown in Figs. 1 and 2 [2,
3, 5]. Early in the third trimester, a striking further
increment occurs that results at term in a tenfold to
twentyfold elevation of plasma aldosterone over
levels measured in the nonpregnant state. Al-
dosterone is not tightly bound to plasma proteins,
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Fig. 1. Mean plasma concentrations of cortisol (F,), desoxycorticosterone (DOC), and aldosterone (ALD) measured sequentially
at 0800 hours during pregnancy and 3 months postpartum. NP denotes not pregnant. (Reprinted with permission from The C. V.
Mosby Company [5])
Fig. 2. Sequential changes in renin substrate concentration,
plasma renin activity, and plasma aldosterone in norm otensive
pregnancy measured in 6-week intervals. (Reprinted with per-
mission of John Wiley & Sons [3]'
so that the rising plasma concentration with advanc-
ing pregnancy presumably results in roughly com-
parable increases in the biologically active free ster-
oid. Nonetheless, the substantial increment in uri-
nary aldosterone excretion observed in pregnancy
is only partly a reflection of the elevation of the cir-
culating level of aldosterone, but is accounted for
largely by the much greater proportion of aldoste-
rone that is metabolized and excreted as the acid-
labile conjugate during pregnancy, which ultimately
is included in usual urinary measurements [8].
Thus, the aldosterone secretion rate is elevated sub-
stantially in pregnancy but not nearly to the same
degree as is the urinary excretion rate.
Plasma renin activity, renin substrate (Fig. 2),
and concentrations of renin and angiotensin II (All)
are also elevated throughout normal gestation [2, 3].
The increase in renin activity parallels aldosterone
levels only in early pregnancy, when it rises rapidly
to a plateau level. Renin activity remains un-
changed in the second and third trimesters, whereas
plasma aldosterone continues to increase [3]. This
suggests that factors other than renin activity and
All may directly stimulate or modulate the produc-
tion of aldosterone in gestation. It has been as-
sumed that most of the increased plasma renin in
pregnancy exists in an inactive form that is activat-
ed when plasma is acidified [9]. Nonetheless, the
plasma concentration of active renin is considerably
higher throughout gestation than it is in non-
pregnant women, although it declines somewhat to-
wards term. Renin-like enzymes, found in the uter-
us and amniotic fluid, do not respond to stimulation
by hemorrhage or acute hyponatremia and there-
fore are not believed to enter the maternal circula-
tion [10]. Increased plasma levels of renin activity
and angiotensin in pregnant women depend there-
fore entirely upon renin secreted by the kidney.
Despite the very high levels of aldosterone, preg-
nant women are quite sensitive to the increased
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sodium-retaining activity that follows the adminis-
tration of mineralocorticoids or adrenocorticotropic
hormone (ACTH) [11, 12]. Prolonged treatment of
normal third trimester women with these agents
results in marked cumulative sodium retention, and
aldosterone excretion is drastically reduced from
very high baseline rates down toward the normal
nongravid range. A representative study of the ef-
fects of DOCA (DOC acetate) in a pregnant woman
is shown in Fig. 3. The lack of refractoriness to the in-
duced increases in sodium-retaining activity suggests
that the very high pretreatment aldosterone levels
were not excessive, because otherwise chronic vol-
ume hyperexpansion should have resulted in "es-
cape" from the effects of further increments in mm-
eralocorticoid activity. The fact that the increased
excretion of aldosterone was so readily suppressed
by volume hyperexpansion resulting from mineral-
ocorticoid administration also argues against exces-
sive aldosterone secretion.1
In contrast to results of comparable studies in
normal nongravidas, as shown in Fig. 3, mineral-
ocorticoid-induced sodium retention in pregnancy
is not accompanied by kaliuresis, even when so-
dium intakes are very high [11]. Refractoriness to
the kaliuretic action of mineralocorticoids during
pregnancy has been attributed to the inhibitory ef-
fect of progesterone. Attenuation of the kaliuretic
influence of mineralocorticoids by progesterone
would also account for the amelioration of hypoka-
lemia that occurs in women with primary aldoste-
ronism when they become pregnant [14].
Aside from observations that aldosterone excre-
tion is readily suppressed by mineralocorticoid-in-
duced volume hyperexpansion, numerous studies
provide additional evidence that aldosterone secre-
tion is regulated by normal mechanisms during
pregnancy. Aldosterone secretion and excretion in
pregnant women vary inversely with changes in salt
intake and increase further in response to volume
depletion by diuretics [15—18]. The degree of change
induced by these maneuvers is comparable to that
observed in nongravidas. Other studies indicate
that the elevated levels of aldosterone and plasma
renin activity in pregnancy also are responsive to
postural changes [19-21]. When third trimester
women in one reported study assumed a supine-up-
right posture after a period of lateral recumbency,
'A sharp decline in the aldosterone excretion rate is noted also
during ACTH administration in pregnant women, which is simi-
lar to the response observed in nongravidas, where the resultant
depression of aldosterone secretion has not necessarily been re-
lated to the degree of sodium retention [12, 13].
sodium retention occurred, associated with a con-
current increase in aldosterone excretion and
plasma renin activity [21]. The increment in aldoste-
rone excretion and renin activity that occurs when
pregnant women assume the supine-upright posture
was similar to that observed in nongravid individ-
uals when they changed to the upright position after
being recumbent.
Because aldosterone secretion in pregnancy re-
sponds normally to physiologic stimuli, it can be
concluded that it is regulated by normal mecha-
nisms and that it increases in normal gestation only
to the extent necessary to maintain sodium balance
and volume homeostasis. Conversely, failure to
maintain the elevated aldosterone levels should re-
sult in salt wasting and hypovolemia. This hypothe-
sis was tested by studies in which aldosterone se-
cretion was directly inhibited without concurrent
volume hyperexpansion by administration of a hep-
arinoid [22]. Heparin and several related heparinoid
derivatives, which are relatively devoid of anti-
coagulant activity, selectively impair aldosterone
production by means of an undefined mechanism.
When the elevated secretion of aldosterone in nor-
mal gravidas was reduced by prolonged treatment
with a heparinoid, marked sodium loss ensued, as
shown in a representative study (Fig. 4). One sub-
ject developed clinical manifestations of volume de-
pletion, characterized by postural weakness and a
slight rise in blood urea nitrogen as aldosterone re-
mained depressed. It is remarkable that sodium loss
occurred during treatment, although aldosterone ex-
cretion, even though greatly diminished as compared
with baseline levels, never was reduced below nor-
mal nonpregnant values. After discontinuation of the
heparinoid, the natriuresis induced by treatment did
not subside until the aldosterone excretion rate re-
turned to the very high baseline rate. The occur-
rence of marked sodium loss despite higher-than-
normal aldosterone excretion provides strong evi-
dence that increased aldosterone secretion is
needed in pregnancy to maintain sodium balance.
Moreover, it supports the proposition that potent
factors oppose the sodium-retaining effects of al-
dosterone during gestation.
Thus, it is noteworthy that when third trimester
pregnant women were studied during extreme die-
tary sodium deprivation, urinary sodium excretion
was reduced to a similar degree, and resultant
weight loss was the same as in nongravidas [7]. At
first glance, these observations seem to offer reas-
surance that the postulated sodium-losing factors in
pregnancy can be countered effectively by com-
pensatory mechanisms. Gravidas normally should
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Fig. 3. Metabolic and aldosterone responses to administered mineralocorticoid in a normal third trimester woman. DOCA is desoxy-
corticosterone acetate. (Reprinted with permission from The Rockefeller University Press [II])
retain 4 to 5 mEq of sodium daily to meet fetal re-
quirements, however, and there should be a weight
gain of 1 lb or more weekly during the third trimes-
ter [23]. Therefore, the fact that urinary sodium ex-
cretion and weight loss were no less than they were
in nongravidas suggests that the maximum sodium-
conserving capability may be impaired in preg-
nancy.
Several known factors in pregnancy promote so-
dium loss and therefore could evoke compensatory
responses, including the rise in aldosterone secre-
tion. The GFR increases by as much as 50%, result-
ing in an increment in the filtered load of sodium of
5000 to 10,000 mEq each day [24]. If enhanced fil-
tration were not countered by a commensurate in-
crease in reabsorption, sodium depletion would rap-
idly ensue. Assuming that glomerulotubular balance
is maintained in pregnancy as in nongravid individ-
uals, there still would be a substantial increase in
the amount of sodium presenting to distal tubular
sites, where a portion of sodium reabsorption is al-
dosterone dependent. The sodium-retaining action
of aldosterone at these distal sites is inhibited, how-
ever, by progesterone, which is secreted in large
amounts during pregnancy. The inhibitory effect of
progesterone, as demonstrated by Landau and Lu-
gibihl in an early study in an Addisonian subject, is
presented in Fig. 5 [25]. Furthermore, progesterone
may also exert a natriuretic effect that is independ-
ent of mineralocorticoid inhibition. Studies of renal
hemodynamics and intrarenal sodium handling dur-
ing administration of progesterone to normal men
show that progesterone may also inhibit sodium
reabsorption at proximal sites in the nephron [26].
Thus, aldosterone would have to increase just to
offset the combined sodium-losing effects of the in-
creased GFR and the natriuretic actions of pro-
gesterone. That progesterone is at least in part re-
sponsible for the rise in aldosterone secretion is
supported by the direct correlation that has been
observed between progesterone and aldosterone se-
cretion in normal pregnant women [8, 27, 28]. Fur-
thermore, administration of progesterone to normal
men results in an initial natriuresis, which sub-
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Fig. 4.Metabolic and aldosterone responses to administration of the heparinoid ROI-8307 to a nor,nal third trimester woman, (Reprinted
with permission from the C. V. Mosby Company [22])
sides promptly as the rate of aldosterone excretion
rises [27]. In addition to countering the above noted
sodium-losing factors, however, normal pregnant
women must retain 500 to 900 mEq of sodium dur-
ing the course of normal gestation to meet the re-
quirements of the developing conceptus and to pro-
vide for the physiologic increase of the maternal in-
terstitial and intravascular fluid volumes [23]. The
need to retain this additional quantity of sodium im-
poses a further stress upon sodium-conserving
mechanisms and provides an additional stimulus for
augmented aldosterone secretion.
The increase in activity of the renin-angiotensin
system and in aldosterone secretion in pregnancy
cannot be attributed entirely to a compensatory re-
sponse to threatened sodium depletion. In one re-
ported study, aldosterone excretion, although
markedly suppressed by prolonged mineral-
ocorticoid administration, remained above the nor-
ma! nongravid rate even though treatment resulted
in cumulative sodium retention of 280 mEq or more
[11]. In another study, plasma renin activity and al-
dosterone concentrations were significantly higher
in pregnant women after 6 days on a 300-mEq so-
dium diet than they were in nonpregnant controls
[7]. Gravidas take longer to come into balance and
retain more sodium, however, than do nongravidas
when given high-sodium diets, consistent with the
proposition that they are relatively sodium depleted
at the outset. Nevertheless, it seems unlikely that
any appreciable degree of sodium depletion still was
present in the pregnant women at the end of the
treatment periods, because they were then in so-
dium balance. Therefore, it must be assumed that
factors other than sodium depletion contributed to
the higher levels of renin activity and aldosterone
secretion that were noted in the pregnant women.
In normal gestation, vascular smooth muscle
tonus and pressor responsiveness to All are re-
duced, presumably due to the action of vasodepres-
sor prostaglandins and progestins [29, 30]. Systemic
peripheral resistance is decreased, and blood pres-
I
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Fig. 5. Effects of progesterone on the urinary excretion of sodium, chloride, potassium, and creatinine in a patient with Addison's
disease. Throughout these observations, the patient received 50 mg of cortisone acetate per day. Broken horizontal lines indicate
averages of control values; oblique hatching indicates significant shifts. (Reprinted with permission from The J. B. Lippincott, Co. [25])
sure falls significantly despite a 25to 50% increment
in cardiac output. Although the extracellular fluid
volume is expanded by 4 to 6 liters, enough to pro-
duce overt edema, heightened activity of the renin-
angiotensin-aldosterone system still is increased
further by changes from lateral recumbent to supine
or upright posture. The briskness of these re-
sponses reflects the marked reduction in the ef-
fective blood volume that occurs when pregnant
women are changed in position from supine recum-
bency, possibly because of enhanced vascular dis-
tensibility and orthostatic pooling of blood from
compression of the inferior vena cava by the
gravid uterus. Even though the renin-angiotensin-
aldosterone system remains extremely responsive
to postural changes, the lowest levels of serum re-
nm activity and rates of aldosterone excretion noted
in pregnant women on normal sodium intakes after
3 days of lateral recumbency still were much higher,
however, than they were in nongravidas, suggesting
that renin release in this instance was being stimu-
lated or modulated by factors not directly related to
decreased vascular tonus [21].
Plasma and urinary prostaglandin E may be in-
creased considerably in normal pregnancy [7].
Aside from their vasodepressor action, prostaglan-
dins of the E type have been shown to enhance re-
nm release and also possibly to increase aldoste-
rone secretion directly [31, 32]. Thus, heightened
activity of the renin-angiotensin-aldosterone system
induced by elevated levels of prostaglandins in
pregnancy might be expected to promote sodium re-
Aldosterone, No aldosterone
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tention whereas blood pressure remains normal be-
cause of the associated vascular refractoriness to
the pressor action of angiotensin. As noted pre-
viously, however, the striking sensitivity of the re-
nin-angiotensin system to postural stimuli observed
in pregnant women is more consistent with a ten-
dency toward functional volume depletion rather
than excessive sodium retention, and it is doubtful
that the elevated levels of plasma renin activity and
aldosterone in pregnancy would be so readily sup-
pressible if either or both were stimulated directly
by increased prostaglandins. On the other hand,
studies in nongravidas seem to indicate that vasode-
pressor prostaglandins tend to enhance responses
of the renin-angiotensin-aldosterone system to so-
dium restriction or diuretic administration [33—36].
Thus, the increased synthesis of vasodepressor
prostaglandins in pregnancy may play an important
role not only in regulation of blood pressure by
modifying sensitivity of vascular smooth muscle to
the pressor effect of angiotensin, but also in volume
homeostasis by modulating responsiveness of the
renin-angiotensin-aldosterone system to volume-
depleting influences. (See contribution by Gant et
al, in this Symposium.)
Desoxycorticosterone in pregnancy
Secretion of desoxycorticosterone (DOC) is
greatly increased in the third trimester of nor-
mal pregnancy as reflected by elevated levels of
plasma DOC and increased excretion of urinary
free DOC as well as of the urinary metabolite, tet-
rahydrodesoxycorticosterone [4, 12]. In the one re-
ported instance where DOC production was mea-
sured by a urinary metabolite isotope dilution meth-
od, the production rate exceeded 8000 pg/day
toward term and fell to a normal value of 174 j.tg/day
on the third day after delivery [4]. Sequential mea-
surements of plasma DOC during normal gesta-
tion reveal that only modest increases occur in the
first two trimesters; the most dramatic increments
were noted in the third trimester when mean DOC
concentrations rose to 60.6 ng!dI compared with
11.2 ng/dl in the nongravid state, as shown in Fig. 1.
Becaus, however, DOC is bound to CBG with
almst the same avidity as is cortisol, it would not
immediately be apparent whether the measured in-
crements in total plasma DOC concentration are
accounted for entirely by the higher levels of CBG
that occur in pregnancy, or whether the biologically
active free moiety is raised above nonpregnant lev-
els. Thus, it is noteworthy that the free DOC in-
dex, which accurately reflects relative differences in
plasma concentrations of free DOC, was greatly
increased above the normal nonpregnant range
when measured in the third trimester women [37].
Furthermore, the markedly elevated rate of urinary
free DOC excretion, 770 ng/day in late pregnancy
compared with 90 ngtday in nongravid controls,
provides additional evidence that the plasma free
DOC concentration is greatly increased, because
the amount of unconjugated, free steroid excreted
in the urine is related directly to the circulating level
of unbound steroid [38, 39].
The mechanisms responsible for the increased se-
cretion of DOC in pregnancy have not been de-
fined. In nongravidas, DOC secretion is not af-
fected directly by factors that influence aldosterone
secretion, but increases in response to ACTH stim-
ulation and is reduced by dexamethasone suppres-
sion [40]. Thus, it has been assumed that the small
amount of DOC secreted in nonpregnant individ-
uals is mainly a byproduct of cortisol biosynthesis,
and accordingly, that it is ACTH-dependent. When
effects of prolonged administration of ACTH were
studied in third trimester women, there was marked
cumulative sodium retention, which was attributed
to enhanced DOC secretion because the high base-
line rate of urinary tetrahydrodesoxycorticosterone
excretion increased sharply during treatment, but
aldosterone was depressed [12]. In later studies,
however, elevated plasma DOC in third trimester
gravidas not only was unresponsive to changes in
salt intake, but, surprisingly, failed to respond to
either ACTH or dexamethasone administration,
whereas plasma cortisol concentrations rose and
fell in normal fashion [37]. The apparent discrepan-
cy between reponses of urinary tetrahydrodesoxy-
corticosterone and plasma DOC to ACTH was
reconciled by a study that took into consideration
binding interactions of DOC and cortisol with
CBG in plasma [37]. Results of this study show that
the free DOC concentration in pregnant subjects
rose significantly during ACTH administration due
to displacement of DOC from CBG by the ACTH-
induced increment in cortisol, even though the total
plasma DOC concentration was virtually un-
changed (Fig. 6). The increase in biologically active
free DOC not only could contribute to the sodium
retention that occurred during ACTH administra-
tion but also would be available for hepatic metabo-
lism to tetrahydrodesoxycorticosterone, thereby
accounting for the increased urinary excretion of
this metabolite. These steroid-binding interactions
have important implications going beyond the
scope of this study, because they identify an addi-
tional mechanism, aside from those regulating se-
cretion, whereby biologic activity of steroids in
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suppressibility of DOC by dexamethasone admin-
istration or during long-term high-salt intake sug-
gests that the increased DOC does not arise from
either glucocorticoid or mineralocorticoid pathways
of the maternal adrenals [37]. Rather, the much
higher concentrations of DOC and DOC sulfate
found in mixed cord blood, compared with maternal
venous blood (Table 1), seem to point to the fetopla-
cental unit as a source of the increased DOC [38].
The fetal-maternal gradient for free DOC would
be even steeper than assumed from the 2 to 3: 1
ratio between measured concentrations of total
DOC, because CBG levels are negligible in fetal
blood [4, 38]. The extremely high concentra-
tions of DOC sulfate noted in cord blood also are
consistent with the proposition that increased
DOC is produced within the fetoplacental unit,
because it is assumed that steroid sulfurylation is
exclusively a fetal process, which in this instance
leads to inactivation of DOC [41, 42]. Thus, it is
tempting to speculate that sulfurylation may afford
a protective mechanism limiting the quantity of ac-
tive DOC contributed to the maternal circulation
by the fetus. On the other hand, the above argu-
ments do not necessarily exclude the possibility
that there also might be significant maternal produc-
tion of DOC. Recently, Winkel et a! presented
evidence that a substantial amount of DOC is pro-
duced within the maternal compartment by extra-
adrenal 21-hydroxylation of progesterone [43]. In
view of the very high plasma levels of progesterone
that occur in pregnancy, it will be interesting to de-
termine if individual differences in the conversion
ratio might occasionally result in pathologic eleva-
tions of DOC from this maternal source.
Regardless of the source, it is apparent that secre-
tion of DOC is elevated substantially in the third
trimester of normal pregnancy and that it is not in-
fluenced by factors that normally regulate adreno-
cortical function. Thus, it is remarkable that normal
third trimester gravidas not only seem to tolerate
very high circulating levels of biologically active
plasma may be modulated. These observations also
underscore the need to use measurements that re-
flect the free steroid fraction, particularly in preg-
nancy where increased quantities of circulating cor-
tisol and progestins compete for binding sites on
elevated CBG levels.
The source of increased DOC secreted in preg-
nancy has not been localized precisely. Non-
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Fig. 6. Plasma concentrations and free indexes of cortisol and
desoxycorticosterone (DOC) in normal third trimester preg-
nant women before and after administration of ACT!!. Six
subjects (.——--.) were treated initially with dexamethasone (2
mg/day in divided doses for 7 days) and subsequently with
ACTH (20 U i.m. every 12 hours for 7 days). Two subjects(. •) received an i.m. injection of 0.25 mg of ACTH, after
overnight suppression with a single dose of 1 mg of dexametha-
sone. Two subjects (S ---- .) were given a 6-hour infusion of 40 U
of ACTH. (Reprinted with permission from The C. V. Mosby
Company [37])
Table 1. Desoxycorticosterone (DOC) and
desoxycorticosterone sulfate (DOC-S) in mixed cord blood
obtained after vaginal delivery and in the plasma of six term
gravidas and of six nonpregnant female controls"
a Values are the means SEM.p <0.001.
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free DOC, but continue to show signs of function-
al hypovolemia, that is, a reduced effective blood
volume. Perhaps the mineralocorticoid activity of
the increased DOC is mitigated to some extent by
the inhibitory action of progesterone, but pregnant
women still are quite sensitive to the sodium-retain-
ing effect of administered DOC, despite their high
levels of progesterone. Thus, excessive increases of
DOC production during pregnancy could lead to
manifestations of mineralocorticoid excess, particu-
larly sodium retention and hypertension. Moreover,
the very high levels of mineralocorticoid activity,
which seem to be well tolerated in normal preg-
nancy, might begin to express themselves in abnor-
mal circumstances and lead to pathologic con-
sequences. Accordingly, with the development of
preeclampsia, aldosterone is depressed, but non-
suppressible DOC, although reported to be no
higher than it is in normotensive subjects, might
then be excessive relative to the existing state of
sodium balance [4].
Salt restriction and diuretics in pregnancy
As opinion has shifted toward the view that nor-
mal pregnancy is associated with a tendency toward
volume depletion, there has been a reappraisal of
previously advocated practices of restricting so-
dium intake and prescribing diuretics during preg-
ancy as prophylaxis against the development of pre-
eclampsia. Several recent reviews, as well as the
report of an Ad Hoc Committee of the American
College of Obstetricians and Gynecologists, have
presented strong admonitions against these prac-
tices [23, 44—47]. Accordingly, it seems appropriate
to restate some of these precautions in the light of
the physiologic concepts presented above.
Although the maternal plasma and interstitial
fluid volumes are increased substantially in preg-
nancy, maternal volume receptors apparently sense
these alterations as normal. As noted above, when
salt restriction or diuretic therapy offsets or limits
the physiologic expansion of these extracellular
fluid spaces, compensatory responses of the renin-
angiotensin-aldosterone system, and presumably,
of other sodium-conserving mechanisms are similar
to those occurring in volume-depleted nonpregnant
subjects. Thus, even though routine treatment with
diuretics or sodium-restricted diets in pregnancy
would seem to be ill-advised, some might argue that
normal compensatory responses would rise to the
occasion, and there would be only a momentary ex-
aggeration of the normal hypovolemic tendency.
There are animal studies, however, that suggest
that the double stress of pregnancy and sodium re-
striction may exceed the adaptive capacity of the
renin-angiotensin-aldosterone system; exhaustion
of adrenal glomerulosa cells occurs, and the animals
become salt depleted [48]. Similarly, the inter-
ruption of normal gestational weight gain observed
in human subjects during prolonged periods of diet-
ary sodium deprivation suggests that the maximum
sodium-conserving capability may be impaired
slightly in pregnancy, enough to result in insidious
sodium wasting when challenged by chronic so-
dium-depleting stresses. Thus, treatment with di-
uretics or sodium restriction may lead to a sufficient
reduction in the intravascular volume to com-
promise placental perfusion. Diuretic therapy has
been shown to reduce the metabolic and placental
clearances of dehydroepiandrosterone sulfate, which
presumably reflect diminished fetoplacental func-
tion [49]. Another serious concern, exemplified by
several reported cases, is that salt depletion in preg-
nancy has resulted in severely impaired renal func-
tion. This complication could easily be misinter-
preted as an evidence of the occurrence or deterio-
ration of preeclampsia, and the need for salt
repletion and cessation of diuretic therapy could
be overlooked [50, 51].
Claims that prophylactic therapy with thiazide di-
uretics reduces the incidence of preeclampsia have
not been substantiated by later studies. Because
proof of benefit currently is lacking and associated
risks are well documented, treatment with diuretics
should be avoided in pregnancy except for heart dis-
ease. Similarly, because routine restriction of die-
tary sodium has not been shown to prevent pre-
eclampsia and may produce complications of so-
dium depletion, pregnant women should be advised
to salt their food according to taste. If the physician
feels compelled to treat asymptomatic edema, bed
rest with the patient positioned in lateral recum-
bency usually promotes adequate diuresis, and if
preeclampsia is suspected, bed rest in the hospital
with careful observation is preferable to diuretic
therapy.
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